Original Articles
 

By Dr. Esther Una Cidon
Corresponding Author Dr. Esther Una Cidon
Oncology Department, Royal Bournemouth Hospital, Castle Lane East - United Kingdom BH7 7DW
Submitting Author Dr. Esther Una Cidon
CANCER

Scalp cooling, Hair loss, Chemotherapy, Alopecia, Breast Cancer, Scalp freezing

Una Cidon E. Scalp cooling use in breast cancer patients receiving neoadjuvant/adjuvant systemic chemotherapy in England. WebmedCentral CANCER 2019;10(9):WMC005592

This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
No
Submitted on: 13 Sep 2019 09:07:33 PM GMT
Published on: 19 Sep 2019 07:15:40 AM GMT

Abstract


Background

Chemotherapy-induced alopecia is a distressing side-effect. Currently the use of scalp cooling has been encouraged but we do not really know the rate of compliance or success in routine practice.

Methods

We have carried out an audit in our centre to assess both, compliance and success in our patients diagnosed with breast cancer who will start chemotherapy with neoadjuvant or adjuvant intent. The degree of hair loss was assessed before cycle 2 and the last cycle, using Dean’s scale.

Results

72 patients were assessed. 27.7% decided to use the scalp cooling, many declined, most of them (61.5%) argued that they were not worried about hair loss. Dean's alopecia score was excellent in 25%, good in 10%, and moderate/poor in 65%.

 

Conclusions

Although scalp cooling may prevent significant alopecia, our patients continue to be reluctant arguing that hair loss does not bother them much. Perhaps the fear of scalp metastases or the reduced benefit from chemotherapy, recognised by patients in forums but not with doctors, need a frank conversation and further education.

BACKGROUND


 

Chemotherapy-induced alopecia is a distressing side-effect that will impact negatively on patient’s personal image (1,2). Since 1970 several preventive measures have been tried but currently all these measures mainly focus on scalp cooling. This has shown some effectiveness in preventing hair loss (1,2).

The extent of alopecia will depend mainly on which agents are used, for how long and the timing (2). Weekly regimens are less likely to cause as significant alopecia as three weekly ones (2).

Scalp cooling caps will cause scalp hypothermia during chemotherapy infusions aiming at reducing the blood flow to the scalp (1). However, this procedure has been thought to increase the risks of cancer recurring in the scalp and some patients complain about feeling uncomfortably cold and having headaches with it as well (3). A recent systematic review of the literature on scalp metastasis following adjuvant chemotherapy for early-stage breast cancer found it unlikely that the incidence might increase after scalp cooling. In fact, it did not demonstrate a statistical difference in the incidence of scalp metastasis between patients using scalp cooling vs. no scalp cooling (3).

Currently the use of scalp cooling has been encouraged but we do not really know the rate of compliance or success in routine practice.

In this context, we decided to carry out an audit of the use and effectiveness of scalp cooling in our patients diagnosed with breast cancer who will receive adjuvant or neoadjuvant chemotherapy.

METHODS


 

We assessed retrospectively patients receiving adjuvant or neoadjuvant chemotherapy for early breast cancer. The study was carried out in the first 6 months of this year.

The degree of hair loss was assessed before cycle 2 and the last cycle.  

The Dean’s scale to assess the grade of hair loss is shown in Table 1.

RESULTS


72 patients were assessed. 27.7% (20/72) decided to use the scalp cooling. The regimens of chemotherapy they received are included on Table 2.

 

Many patients declined the use of scalp cooling and the reasons for this appear on Table 3. Most patients (61.5%) argued that they were not worried about hair loss.

The age of patients receiving chemotherapy and their decision regarding the scalp cooling is reported on Table 4, including the results of its use.

One patient kept the hair even though she declined the use of the cold cap. She was receiving weekly Paclitaxel and before last cycle she had a grade 1 alopecia in Dean’s scale.   

According to our data, the highest proportion of patients accepting the cold cap is within the youngest population followed by the group of patients in their 60s. 

The effectiveness in our group of patients according to Dean’s scale was assessed prior to second cycle and final cycle. This last one is reported on Table 5.

Prior to cycle 2 most patient kept their hair even without the use of scalp cooling although most of them had noticed grade 1 alopecia.

Dean's alopecia score was excellent for 25% of patients (grade 0, 1), good for 10% of patients, and moderate or poor (grade 3, 4) for 65% of patients.

The adverse events and frequency are reported on Table 6. 

The majority of patients reported hair thinning after every chemotherapy cycle. One patient discontinued scalp cooling due to headaches/migraine induced by scalp cooling.

Table 1: Dean’s scale of alopecia

Grade of alopecia

Hair loss percentage

Grade 0

No hair loss

Grade 1

< 25%

Grade 2

25-50%

Grade 3

50-75%

Grade 4

>75%


Table 2: Regimens of chemotherapy

 

Regimen

 

N

Use of cold cap

Yes

No

FEC/T

15

7

8

TCHP

52

9

43

THP

1

1

0

Weekly Paclitaxel

3

2

1

TC

1

1

0

Total

72

20

52

                & nbsp;                 ;   T – Docetaxel, C – Cyclophosphamide, E – Epirubicin

 

Table 3: Reasons for declining scalp cooling

Reasons for declining

N

Not worried about hair loss

32

Fear of bad experience

8

Previous headaches

8

Fear of scalp metastases

4


Table 4: Age and scalp cooling use

Age

Used scalp cooling

Declined scalp cooling

 

% use vs decline

Hair lost*

Hair kept

Hair lost*

Hair kept

≥ 70

2

2

7

1

33%

≥ 60

5

2

10

0

41%

≥ 50

1

1

18

0

10%

≥ 40

1

2

11

0

21%

≥ 20

4

0

5

0

44%

TOTAL

20

52

 

*(Dean’s grade ≥ 3)

 

Table 5: Effectiveness of scalp cooling before last cycle

Grade of alopecia

Hair loss percentage

N

Score

%

Grade 0

No hair loss

1

 

Excellent

 

35%

Grade 1

< 25%

4

Grade 2

25-50%

2

Good

Grade 3

50-75%

3

 

Poor

 

65%

Grade 4

>75%

10

Table 6: Toxicities and frequency with scalp cooling

 

Toxicities

N

Abandoned due to toxicities

Headaches

4

1

Discomfort

3

0


CONCLUSION


As a routine we offer scalp cooling to all our patients who will start adjuvant or neoadjuvant chemotherapy for early breast cancer. The risk of scalp metastases is explained but informing that systematic reviews do not seem to support that.

In our population of patients, only one patient abandoned the scalp cooling due to migraines not responding to Paracetamol but following the general recommendations (such as using Paracetamol routinely before the scalp cooling is fitted) no other patients stopped using it due to toxicities.

In our group of patients, we only achieved good/excellent score in around 35% but in several patients considered to have a poor score, this was due to badly fitted cap. We plan to increase the effectiveness by ensuring tight fit especially on crown for all patients.

REFERENCES


  1. Scalp cooling. https://www.macmillan.org.uk/information-and-support/coping/side-effects-and-s ymptoms/hair-loss/scalp-cooling.html
  2. Vasconcelos IWiesske ASchoenegg W. Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy. Breast. 2018 Aug;40:1-3. doi: 10.1016/j.breast.2018.04.012. Epub 2018 Apr 13.
  3. Hope S. Rugo, Paula Klein, Susan Anitra Melin, et al. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017;317(6):606-614. doi:10.1001/jama.2016.21038

 

Source(s) of Funding


NHS 

Competing Interests


n/a

Reviews
0 reviews posted so far

Comments
0 comments posted so far

Please use this functionality to flag objectionable, inappropriate, inaccurate, and offensive content to WebmedCentral Team and the authors.

 

Author Comments
0 comments posted so far

 

What is article Popularity?

Article popularity is calculated by considering the scores: age of the article
Popularity = (P - 1) / (T + 2)^1.5
Where
P : points is the sum of individual scores, which includes article Views, Downloads, Reviews, Comments and their weightage

Scores   Weightage
Views Points X 1
Download Points X 2
Comment Points X 5
Review Points X 10
Points= sum(Views Points + Download Points + Comment Points + Review Points)
T : time since submission in hours.
P is subtracted by 1 to negate submitter's vote.
Age factor is (time since submission in hours plus two) to the power of 1.5.factor.

How Article Quality Works?

For each article Authors/Readers, Reviewers and WMC Editors can review/rate the articles. These ratings are used to determine Feedback Scores.

In most cases, article receive ratings in the range of 0 to 10. We calculate average of all the ratings and consider it as article quality.

Quality=Average(Authors/Readers Ratings + Reviewers Ratings + WMC Editor Ratings)